Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers
Rhea-AI Summary
Immunovia (NASDAQ Stockholm: IMMNOV) will present results from its recently completed model-development study of their next-generation pancreatic cancer detection test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC). The company's abstract was accepted and recognized for inclusion in the Henry Lynch Lecture. Immunovia is currently conducting a clinical validation study of its next-generation test, expected to complete in December 2024, with plans to launch the test in 2025. The company estimates that in the USA, 1.8 million individuals at high-risk for pancreatic cancer could benefit from annual surveillance testing.
Positive
- Clinical validation study of next-generation pancreatic cancer test on track for completion in December 2024
- Large potential market with 1.8 million high-risk individuals in the USA who could benefit from annual testing
- Abstract accepted and recognized at prestigious CGA-IGC conference
Negative
- Product launch not expected until late 2025, indicating significant time before potential revenue generation
The Scientific Committee of the CGA-IGC evaluated and accepted Immunovia's abstract, which reports outcomes from the company's model-development study, for presentation at the meeting. Immunovia's submission was also recognized for inclusion in the Henry Lynch Lecture during the conference.
The Collaborative Group of the
Immunovia will share results from the model-development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. In addition, the company provided a grant to fund an educational symposium at the meeting titled "Increasing Access to Pancreatic Cancer Screening: Lessons Learned from a Community-Based High-Risk Screening Program." The symposium, led by Ora Gordon, MD, and Miles Picus, LCGC, will discuss the implementation of a high-risk pancreatic cancer surveillance program and early detection tests.
"CGA-IGC's annual meeting is a premier event for clinicians focused on inherited gastrointestinal cancers and we are thrilled to be selected to share the results of our model-development study," said Jeff Borcherding, Chief Executive Officer at Immunovia.
Immunovia is currently conducting a clinical validation study of its next-generation test, which is expects to complete in December 2024. The company plans to launch the test later in 2025.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist-Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-presents-model-development-study-results-at-meeting-of-the-collaborative-group-of-the-americasinherited-gastrointestinal-cancers-302306877.html
SOURCE Immunovia AB
FAQ
When will Immunovia (IMMNOV) complete the clinical validation study for its pancreatic cancer test?
What is the target market size for Immunovia's (IMMNOV) pancreatic cancer test in the USA?
When does Immunovia (IMMNOV) plan to launch its next-generation pancreatic cancer test?
